홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Candesartan Cilexetil

HCID 2540
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
145040-37-5
표준 SMILES
CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
InChIKey
GHOSNRCGJFBJIB-UHFFFAOYSA-N
분자식
C33H34N6O6
평균 분자량
610.7 g/mol
단동위원소 질량
610.25398283

개요

Candesartan cilexetil is a member of biphenyls.

이름 및 식별자

우선 이름
Candesartan Cilexetil
IUPAC
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
영어명
Candesartan cilexetil
분자식
C33H34N6O6
분자량
610.66

이름 및 동의어

Candesartan cilexetil145040-37-5AtacandTCV-116AmiasDTXSID5020239NSC-758697R85M2X0D68DTXCID50239Candesartan 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester1H-Benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)-Candesartan 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester
이름 더 보기
Candesartan cilexetiBlopressCandesartan cilexetil for peak identificationtcv116exetiLTCY 116CandestartanCandesartan CiLCadesartan cilexetil
RefChem:566661-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate(1RS)-1-(Cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-benzimidazole-7-carboxylateRatacandParapresKenzencandesartancilexetilCANDESARTAN CILEXTIL

물성

구조 계산 물성

XLogP
7
극성 표면적
143 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
10
회전 가능 결합 수
13
무거운 원자 수
45
형식 전하
0
복잡도
962

실험 및 물리화학적 성질

Drugs · 2건

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals

Human Drugs · 2건

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Collision Cross Section · 2건

242.2 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID5020239]

241.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

물리화학적 성질

녹는점
168 · 168-170C
끓는 점
843.3 · 843.3±75.0 °C(Predicted)
밀도
1.37 · 1.37±0.1 g/cm3(Predicted)
저장 조건
2 · 2-8°C
용해도
15 mg/mL · DMSO: ≥15mg/mL
산도 계수 (pKa)
3.55 · pKa 3.55 (H2O t=25.0 I=0.025) (Uncertain);5.91(H2O t=25.0 I=0.025) (Uncertain)
물리적 상태
가루
색상
흰색에서 베이지색
Merck
14 · 14,1739
BCS Class

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 5건

This chemical does not meet GHS hazard criteria for 0.5% (1 of 197) of reports.

Danger

H302 (26.9%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P261, P263, P264, P264+P265, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 197 reports by companies from 20 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Hazard Classes and CategoriesAcute Tox. 4 (26.9%)

독성 정보

Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Candesartan cilexetil

vLess-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

EPA Human Health Benchmarks for Pharmaceuticals · 6건

Candesartan cilexetil

0.2

0.8

Blood pressure response is dose related over the range of 2 to 32 mg. Candesartan cilexetil tablets can be administered once or twice daily with total daily doses ranging from 8 mg to 32 mg.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 8 mg/day, Lowest Therapeutic Dose (LTD): 0.1 mg/kg-day, and Screening Dose: 0.00003 mg/kg-day.

27-Jun-17

안전 데이터

wgk
3

화학 및 산업

약리 정보

Protein BindingCandesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells.
Pharmacodynamics · 1건

Candesartan cilexetil is an ARB prodrug that is rapidly converted to candesartan, its active metabolite, during absorption from the gastrointestinal tract. Candesartan confers blood pressure lowering effects by antagonizing the hypertensive effects of angiotensin II via the RAAS. RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: type-1 angiotensin II receptor (AT1) and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.

Mechanism of Action · 1건

Candesartan selectively blocks the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. This inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in an overall decrease in blood pressure. Candesartan is greater than 10,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion.

Biological Half-Life

관련 반응

11건
반응 기록 만들기
HRID 11804 반응식
HRID 11804생성물로
HRID 11805 반응식
HRID 11805생성물로
HRID 11806 반응식
HRID 11806생성물로
HRID 11807 반응식
HRID 11807생성물로
HRID 324526 반응식
HRID 324526반응물로
HRID 549973 반응식
HRID 549973반응물로
HRID 640734 반응식
HRID 640734반응물로
HRID 640735 반응식
HRID 640735생성물로
이전1 / 2 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

데이터베이스 식별자

CAS
145040-37-5
PubChem CID
2540
DTXSID
DTXSID5020239
ChEMBL
CHEMBL1014
ChEBI
CHEBI:3348
UNII
R85M2X0D68
EC Number
627-030-2
Nikkaji
J1.640.921I
2 · 2
주요 응용
의약품(소분자)
InChIKey
GHOSNRCGJFBJIB-UHFFFAOYSA-N
SMILES
C1(OCC)N(CC2=CC=C(C3=CC=CC=C3C3=NNN=N3)C=C2)C2=C(C(OC(OC(OC3CCCCC3)=O)C)=O)C=CC=C2N=1

화학적 성질

It appears as a white or off-white powder.It is soluble in methanol but insoluble in water.

rtecs
DD6672500
독성
dog,LD50,oral,> 2gm/kg (2000mg/kg),Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 42, Pg. 406, 2000.
HS 번호
2933990099
risk_code
20/21/22-36/37/38-50-48/20-61
hazard_code
Xn,N,T
safety_code
26-36-61-45-53
Hazard Classifications
Repr. 1BSTOT RE 2 Oral
스토리지 클래스
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Approximately 9 hours.
Metabolism/Metabolites · 1건

The prodrug candesartan cilexetil undergoes rapid and complete ester hydrolysis in the intestinal wall to form the active drug, candesartan. Elimination of candesartan is primarily as unchanged drug in the urine and, by the biliary route, in the feces. Minor hepatic metabolism of candesartan (<20%) occurs by O-deethylation via cytochrome P450 2C9 to form an inactive metabolite. Candesartan undergoes N-glucuronidation in the tetrazole ring by uridine diphosphate glucuronosyltransferase 1A3 (UGT1A3). O-glucuronidation may also occur. 75% of candesartan is excreted as unchanged drug in urine and feces.

FDA Pharmacological Classification · 2건

CANDESARTAN CILEXETIL

Angiotensin 2 Receptor Blocker [EPC]; Angiotensin 2 Receptor Antagonists [MoA]

MeSH Pharmacological Classification · 2건

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.

Absorption, Distribution and Excretion · 4건

Following administration of the candesartan cilexetil prodrug, the absolute bioavailability of candesartan was estimated to be 15%. Food with a high fat content has no effect on the bioavailability of candesartan from candesartan cilexetil.

When candesartan is administered orally, about 26% of the dose is excreted unchanged in urine. Candesartan is mainly excreted unchanged in urine and feces (via bile).

0.13 L/kg

0.37 mL/min/kg

용도 및 제조

UsesUse (kg) in Switzerland (2009): >500

응용 분야

일반 설명Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards

상·하류 제품 정보

상류 원료

1-요오도에틸사이클로헥실카보네이트황산아지도트리메틸틴트리틸클로라이드수산화나트륨3-나이트로프탈산탄산 칼륨4-Bromomethyl-2-cyanobiphenyl소디움 아지이드염화 제일석